FPGEE key terms

The fraction of an administered dose of a drug that reaches the systemic circulation unchanged, expressed as a percentage. Intravenous administration is defined as 100 percent; oral values are lower when absorption or first-pass metabolism limits entry.

A calculated apparent volume relating the total amount of drug in the body to its plasma concentration. Large values suggest extensive distribution into tissues; small values suggest the drug remains largely in the bloodstream.

The volume of plasma from which a drug is completely removed per unit time. It determines the maintenance dose rate needed to sustain a target steady-state concentration, independent of the volume of distribution.

The time required for the plasma concentration of a drug to fall by half during elimination. It reflects the ratio of volume of distribution to clearance and governs how quickly a drug accumulates or disappears.

Breakdown of an orally absorbed drug by enzymes in the intestinal wall or liver before it reaches the systemic circulation, reducing oral bioavailability and often requiring larger oral than intravenous doses.

The condition during repeated dosing when the amount of drug entering the body equals the amount eliminated per dosing interval, so concentrations fluctuate around a stable average, typically reached after four to five half-lives.

An initial larger dose given to raise plasma drug concentrations rapidly toward a therapeutic target, calculated from the volume of distribution and the desired concentration rather than from clearance.

The demonstration that two drug products deliver the same active ingredient into the bloodstream at a comparable rate and extent, usually assessed by comparing total exposure and peak concentration within accepted statistical limits.

The lowest concentration of an antimicrobial agent that prevents visible growth of a standardized bacterial inoculum under defined laboratory conditions, used to classify organisms as susceptible, intermediate, or resistant.

Coating of a pathogen with antibodies or complement proteins so that phagocytic cells recognize and engulf it more efficiently, linking humoral immunity to cellular clearance of microbes.

An amphiphilic molecule with both water-loving and fat-loving regions that lowers interfacial tension, allowing oils and water to mix and stabilizing emulsions, suspensions, and powder wetting.

The description of saturable drug elimination in which clearance is roughly first order at low concentrations but approaches a fixed maximum rate at high concentrations, so small dose increases can cause disproportionate accumulation.

The specific three-dimensional arrangement of chemical features in a molecule that is required for biological activity at a target, serving as a template for designing new active compounds.

The study of how systematic changes in a molecule's chemical structure alter its potency, selectivity, and safety, used to guide optimization of lead compounds into drug candidates.

A ligand that binds and activates a receptor but produces a smaller maximal response than a full agonist, and can reduce the effect of a full agonist when both are present.

A ligand that binds reversibly at the same site as the agonist, produces no activation, and shifts the agonist dose-response curve to the right without lowering the maximal response.

A ratio comparing the dose producing toxicity with the dose producing the desired effect; a small ratio means therapeutic and toxic doses are close, requiring cautious dosing and monitoring.

An increase in liver enzyme production after repeated exposure to a drug or chemical, which speeds metabolism of the inducing agent and of other drugs, lowering their concentrations and possibly their effectiveness.

A molecule that binds metal ions at multiple sites to form a stable ring-shaped complex, used to treat heavy-metal poisoning by promoting urinary excretion of the metal.

The logarithm of a compound's partition coefficient between octanol and water, a measure of lipophilicity that predicts membrane permeability, tissue distribution, and metabolic behavior.

Rapid loss of a drug's effect after repeated doses over a short period, often from depletion of mediators or receptor desensitization, and distinct from slower-developing tolerance.

Measurement of drug concentrations in blood with interpretation to individualize dosing, used for drugs with narrow therapeutic ranges, unpredictable pharmacokinetics, or concentration-related toxicity.

An unintended, harmful response to a medicine used at normal doses, ranging from predictable dose-related effects to unpredictable immune or idiosyncratic reactions that require dose change or discontinuation.

The strongest safety warning required by regulators on a prescription drug's labeling, highlighting serious or life-threatening risks and shaping prescribing, monitoring, and patient counseling decisions.

Prescribing an approved medicine for a dose, indication, patient population, or route not covered by its regulatory approval, a lawful practice that should rest on sound published evidence.

Systematically developed statements that recommend appropriate treatment for specific clinical circumstances, synthesized from evidence and expert judgment to standardize and improve patient care.

The number of patients who must receive an intervention for one additional patient to benefit, calculated as the reciprocal of the absolute risk reduction; smaller values indicate greater benefit.

A measure combining length of life with health-related quality of life, in which one year in perfect health equals one; used to compare value across treatments and inform resource allocation.

The ratio of the difference in cost between two interventions to the difference in their health outcomes, commonly expressed as the added cost per quality-adjusted life year gained.

A continually updated list of medicines approved for use within a health system, maintained by a committee that evaluates efficacy, safety, and cost to guide prescribing decisions.

The extent to which a patient takes medicines as agreed with the prescriber, including timing, dose, and duration; poor adherence is a common and modifiable cause of treatment failure.

A structured process of comparing a patient's complete medication list across care transitions and resolving discrepancies to prevent omissions, duplications, and dosing errors.

A patient-centered practice model in which the pharmacist accepts responsibility for identifying and resolving drug-related problems and for achieving definite outcomes that improve the patient's quality of life.

A patient's voluntary agreement to a treatment or service after receiving and understanding information about its purpose, benefits, risks, and alternatives, documented in the health record.

The date after which a compounded preparation must not be used, assigned from stability data and based on the formulation, container, storage conditions, and water content.

A labeling convention that capitalizes the distinguishing parts of look-alike drug names, such as hydrOXYzine versus hydrALAZINE, to reduce selection and dispensing errors.

The science of detecting, assessing, understanding, and preventing adverse effects or other drug-related problems, relying on spontaneous reporting systems and postmarketing surveillance data.